Neusoft Medical’s Cardiology CAD Software Gets SFDA Nod
This article was originally published in PharmAsia News
Executive Summary
Neusoft Medical System has received China's State FDA approval for its Cardiology Computer-Aided Diagnosis (CAD) 2.0 system. This is the second SFDA certification for the company's CAD software, the first being MammoCAD. Clinical testing of CardioCAD2.0 shows that its effectiveness and safety standards are equal to world-class products, providing doctors an analysis platform of heart vessel CT images. CardioCAD's successful development by a Chinese firm represents a significant milestone for the specialized field; it not only breaks the monopoly MNCs hold in domestic and international markets, but also brings new choices to the health care industry. (Click here for more - Chinese Language)
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.